Nickolas A. Sophos

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

Hope S. Rugo, Florence Lerebours, Eva Ciruelos et al. · The Lancet Oncology · 2021 · 340 citations

Breast Oncology, Oncology, Medicine +9

Aldehyde dehydrogenase gene superfamily: the 2002 update

Nickolas A. Sophos, Vasilis Vasiliou · Chemico-Biological Interactions · 2003 · 333 citations

Biosynthesis, Aldehyde Dehydrogenase, Biochemistry +5

Aldehyde dehydrogenase gene superfamily: the 2000 update

Nickolas A. Sophos, Aglaia Pappa, Thomas Ziegler et al. · Chemico-Biological Interactions · 2001 · 88 citations

Biosynthesis, Aldehyde Dehydrogenase, Biochemistry +5

Corneal and stomach expression of aldehyde dehydrogenases: from fish to mammals

Aglaia Pappa, Nickolas A. Sophos, Vasilis Vasiliou · Chemico-Biological Interactions · 2001 · 59 citations

Aldehyde Dehydrogenase, Biochemistry, Corneal Dystrophy +7

Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with <i>PIK3CA-</i>mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results.

Hope S. Rugo, Florence Lerebours, Eva Ciruelos et al. · Journal of Clinical Oncology · 2020 · 56 citations

Breast Oncology, Pathology, Tumor Biology +17